Comparison of Genomic and Infection Characteristics of Coronavirus

doi:10.13523/j.cb.2005012

China Biotechnology

2020, Vol. 40

Issue (11): 56-66 DOI: 10.13523/j.cb.2005012

Comparison of Genomic and Infection Characteristics of Coronavirus

CHENG Zi-zhao¹,CHEN Chu-chu¹,YING Lei²,LI Xiao-kun¹,HUANG Zhi-feng^1**(

)

1 School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China
2 School of Basic Medical Science, Wenzhou Medical University, Wenzhou 325035, China

Download:

HTML

PDF(5578KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Coronavirus is a kind of pathogen that can cause respiratory and digestive diseases. At present, the understanding of coronavirus is not deep enough, and the similarities and differences between SARS-CoV-2 and other human coronaviruses in biological characteristics, infection mechanism, epidemiology and clinical characteristics are not clear. By summarizing the characteristics of several coronaviruses including SARS-CoV-2, and analyzes the susceptibility and prognosis of SARS-CoV-2 in special population, so as to provide reference for clinical research and differential diagnosis.

Key words： Coronavirus Genome structure Infection mechanism Epidemiology Clinical characteristics

Received: 07 May 2020 Published: 11 December 2020

ZTFLH:

Q939.4

Corresponding Authors: Zhi-feng HUANG E-mail: hzf@wmu.edu.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zi-zhao CHENG
	Chu-chu CHEN
	Lei YING
	Xiao-kun LI
	Zhi-feng HUANG

Cite this article:

CHENG Zi-zhao,CHEN Chu-chu,YING Lei,LI Xiao-kun,HUANG Zhi-feng. Comparison of Genomic and Infection Characteristics of Coronavirus. China Biotechnology, 2020, 40(11): 56-66.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2005012 OR https://manu60.magtech.com.cn/biotech/Y2020/V40/I11/56

Table1 Basic information of various coronaviruses

Fig.1 Genome map of various coronaviruses The complete coronavirus genome includes 5'leading sequence, open reading frame 1a/b, spinous process genes (S), envelope genes (E), membrane genes (M), nucleocapsid genes (N) and a series of auxiliary protein genes. The open reading frame 1a/b accounts for about 2/3 of the whole genome and encodes 16 nonstructural proteins (nsp1 to nsp16). The arrows indicate 15 restriction sites

Table 2 Various coronaviruses and their functional receptors

Table 3 Epidemiological and clinical characteristics of various coronaviruses


[1]	Worldometer. COVID-19 Coronavirus Pandemi. [2020-08-18]. https://www.worldometers.info/coronavirus/?from=singlemessage#countries.

[2]	Neuman B W, Adair B D, Yoshioka C, et al. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. J Virol, 2006,80(16):7918-7928. doi: 10.1128/JVI.00645-06 pmid: 16873249

[3]	Hamre D, Procknow J J. A new virus isolated from the human respiratory tract. Proceedings of the Society for Experimental Biology & Medicine, 1966,121(1):190-193.

[4]	Pyrc K, Jebbink M F, Berkhout B, et al. Genome structure and transcriptional regulation of human coronavirus NL63. Virol J, 2004,1:7. pmid: 15548333

[5]	Van der Hoek L, Pyrc K, Berkhout B. Human coronavirus NL63, a new respiratory virus. FEMS Microbiology Reviews, 2006,30(5):760-773. doi: 10.1111/j.1574-6976.2006.00032.x pmid: 16911043

[6]	胡琴, 谭文杰. 人冠状病毒HCoV-OC43的研究进展. 中华预防医学杂志, 2013,47(7):661-664.

[6]	Hu Q, Tan W J. Research progress of human coronavirus HCoV-OC43. Chinese Journal of Preventive Medicine, 2013,47(7):661-664.

[7]	Mcintosh K, Dees J H, Becker B W, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA, 1967,57(4):933-940. doi: 10.1073/pnas.57.4.933 pmid: 5231356

[8]	Woo P, Lau S, Yip C, et al. More and more coronaviruses: Human coronavirus HKU1. Viruses, 2009,1(1):57-71. doi: 10.3390/v1010057 pmid: 21994538

[9]	刘培林, 史蕾, 顾大勇, 等. 人冠状病毒HCoV-HKU1研究进展. 中国公共卫生, 2017,33(8):1264-1266.

[9]	Liu P L, Shi L, Gu D Y, et al. Research progress of human coronavirus HCoV-HKU1. Chin J Publ Heal, 2017,33(8):1264-1266.

[10]	Rota P A, Oberste M S, Monroe S S, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science, 2003,300(5624):1394-1399. pmid: 12730500

[11]	Weiss S R, Leibowitz J L. Coronavirus pathogenesis. Adv Virus Res, 2011,81:85-164. pmid: 22094080

[12]	Zaki A M, Boheemen S V, Bestebroer T M, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med, 2012,367(19):1814-1820. doi: 10.1056/NEJMoa1211721 pmid: 23075143

[13]	Chan J F, Kok K H, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect, 2020,9(1):221-236. doi: 10.1080/22221751.2020.1719902 pmid: 31987001

[14]	Han Q, Lin Q, Jin S, et al. Coronavirus 2019-nCoV: A brief perspective from the front line. J Infect, 2020,80(4):373-377. doi: 10.1016/j.jinf.2020.02.010 pmid: 32109444

[15]	Oong X Y, Ng K T, Takebe Y, et al. Identification and evolutionary dynamics of two novel human coronavirus OC43 genotypes associated with acute respiratory infections: phylogenetic, spatiotemporal and transmission network analyses. Emerg Microbes Infect, 2017,6(1):e3. doi: 10.1038/emi.2016.132 pmid: 28050020

[16]	Pyrc K, Berkhout B, van der Hoek L. The novel human coronaviruses NL63 and HKU1. J Virol, 2007,81(7):3051-3057. doi: 10.1128/JVI.01466-06 pmid: 17079323

[17]	Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol, 2020,92(4):418-423. pmid: 31967327

[18]	Fehr A R, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol Biol, 2015,1282:1-23. doi: 10.1007/978-1-4939-2438-7_1 pmid: 25720466

[19]	GISAID. GISAID EpiCoV Database.[2020-08-18]. https://db.cngb.org/gisaid/.

[20]	Lokman S M, Rasheduzzaman M, Salauddin A, et al. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach. Infect Genet Evol, 2020,84:104389. doi: 10.1016/j.meegid.2020.104389 pmid: 32502733

[21]	Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Microbiology, 2020,7(6):1012-1023.

[22]	Korber B, Fischer W M, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell, 2020,18(4):812-827.

[23]	Tortorici M A, Walls A C, Lang Y, et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol, 2019,26(6):481-489. pmid: 31160783

[24]	Li Z J, Tomlinson A C, Wong A H, et al. The human coronavirus HCoV-229E S-protein structure and receptor binding. [2020-08-18]. https://elifesciences.org/articles/51230

[25]	Vennema H, Godeke G J, Rossen W A J, et al. Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes. The EMBO Journal, 1996,15(8):2020-2028. pmid: 8617249

[26]	Wilson L, McKinlay C, Gage P, et al. SARS coronavirus E protein forms cation-selective ion channels. Virology, 2004,330(1):322-331. pmid: 15527857

[27]	Yount B, Denison M R, Weiss S R, et al. Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol, 2002,76(21):11065-11078. doi: 10.1128/jvi.76.21.11065-11078.2002 pmid: 12368349

[28]	Schelle B, Karl N, Ludewig B, et al. Selective replication of coronavirus genomes that express nucleocapsid protein. J Virol, 2005,79(11):6620-6630. doi: 10.1128/JVI.79.11.6620-6630.2005 pmid: 15890900

[29]	Wurm T, Chen H, Hodgson T, et al. Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division. J Virol, 2001,75(19):9345-9356.

[30]	Yeager C L, Ashmun R A, Williams R K, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature, 1992,357(6377):420-422. pmid: 1350662

[31]	Hofmann H, Pyrc K, van der Hoek L, et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci USA, 2005,102(22):7988-7993. doi: 10.1073/pnas.0409465102 pmid: 15897467

[32]	Wu C. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV, in the nasal tissue. [2020-8-18]. https://www.medrxiv.org/content/10.1101/2020.02.11.20022228v2.

[33]	Hulswit R J G, Lang Y, Bakkers M J G, et al. Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc Natl Acad Sci USA, 2019,116(7):2681-2690.

[34]	Huang X, Dong W, Milewska A, et al. Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J Virol, 2015,89(14):7202-7213. doi: 10.1128/JVI.00854-15 pmid: 25926653

[35]	Li W H, Moore M J, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003,426(6965):450-454. doi: 10.1038/nature02145 pmid: 14647384

[36]	Raj V S, Mou H H, Smits S L, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature, 2013,495(7440):251-254. pmid: 23486063

[37]	Lambeir A M, Durinx C, Scharpé S, et al. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crc Critical Reviews in Clinical Laboratory Sciences, 2003,40(3):209-294. doi: 10.1080/713609354 pmid: 12892317

[38]	Yeager C L, Ashmun R A, Williams R K, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature, 1992,357(6377):420-422. doi: 10.1038/357420a0 pmid: 1350662

[39]	Kawase M, Shirato K, Matsuyama S, et al. Protease-mediated entry via the endosome of human coronavirus 229E. J Virol, 2009,83(2):712-721. pmid: 18971274

[40]	Bertram S, Dijkman R, Habjan M, et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol, 2013,87(11):6150-6160. doi: 10.1128/JVI.03372-12 pmid: 23536651

[41]	Milewska A, Zarebski M, Nowak P, et al. Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol, 2014,88(22):13221-13230. doi: 10.1128/JVI.02078-14 pmid: 25187545

[42]	Bakkers M J, Lang Y F, Feitsma L J, et al. Betacoronavirus adaptation to humans involved progressive loss of hemagglutinin-esterase lectin activity. Cell Host Microbe, 2017,21(3):356-366. pmid: 28279346

[43]	Vlasak R, Luytjes W, Spaan W, et al. Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci USA, 1988,85(12):4526-4529. doi: 10.1073/pnas.85.12.4526 pmid: 3380803

[44]	Lim Y X, Ng Y L, Tam J P, et al. Human coronaviruses: A review of virus-host interactions. Diseases, 2016,4(3):26. doi: 10.3390/diseases4030026

[45]	Dominguez S R, Travanty E A, Qian Z H, et al. Human coronavirus HKU1 infection of primary human type II alveolar epithelial cells: cytopathic effects and innate immune response. PLoS One, 2013,8(7):e70129. pmid: 23894604

[46]	Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 2005,436(7047):112-116.

[47]	Simmons G, Gosalia D N, Rennekamp A J, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA, 2005,102(33):11876-11881. pmid: 16081529

[48]	Matsuyama S, Nagata N, Shirato K, et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol, 2010,84(24):12658-12664.

[49]	Glowacka I, Bertram S, Muller M A, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol, 2011,85(9):4122-4134.

[50]	Zhu X J, Liu Q, Du L Y, et al. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis, 2013,5(Suppl 2):S142-148.

[51]	Lu G W, Hu Y W Wang Q H, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature, 2013,500(7461):227-231.

[52]	Hocke A C, Becher A, Knepper J, et al. Emerging human middle east respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. American Journal of Respiratory & Critical Care Medicine, 2013,188(7):882-886.

[53]	Doremalen N V, Miazgowicz K L, Milne-Price S, et al. Host species restriction of middle east respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol, 2014,88(16):9220-9232.

[54]	Barlan A, Zhao J C, Sarkar M K, et al. Receptor variation and susceptibility to middle east respiratory syndrome coronavirus infection. J Virol, 2014,88(9):4953-4961. pmid: 24554656

[55]	Xu X T, Chen P, Wang J F, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci, 2020,63(3):457-460.

[56]	Tai W B, He L, Zhang X J, Pu J, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol, 2020,17(6):613-620

[57]	Wong S H, Lui R N, Sung J J. Covid-19 and the digestive system. J Gastroenterol Hepatol, 2020,35(5):744-748. doi: 10.1111/jgh.15047 pmid: 32215956

[58]	Xu H, Zhong L, Deng J X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci, 2020,12(1):8. pmid: 32094336

[59]	Che X Y, Qiu L W, Liao Z Y, et al. Antigenic cross-reactivity between severe acute respiratory syndrome: associated coronavirus and human coronaviruses 229E and OC43. Journal of Infectious Diseases, 2005,191(12):2033-2037.

[60]	Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med, 2015,13:210.

[61]	Hunter J C, Nguyen D, Aden B, et al. Transmission of middle east respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi Emerg Infect Dis, 2016,22(4):647-656.

[62]	Anderson R M, Fraser C, Ghani A C, et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci, 2004,359(1447):1091-1105. doi: 10.1098/rstb.2004.1490 pmid: 15306395

[63]	de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol, 2016,14(8):523-534. doi: 10.1038/nrmicro.2016.81 pmid: 27344959

[64]	Leung G M, Hedley A J, Ho L M, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Annals of Internal Medicine, 2004,141(9):662-673.

[65]	Cowling B J, Park M, Fang V J, et al. Preliminary epidemiologic assessment of MERS-CoV outbreak in South Korea, May-June 2015. Euro Surveill, 2015,20(25):7-13.

[66]	Tsui P T, Kwok M L, Yuen H, et al. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerging Infectious Diseases, 2003,9(9):1064-1069.

[67]	Fisman D N. Hemophagocytic syndromes and infection. Emerging Infectious Diseases, 2000,6(6):601-608. doi: 10.3201/eid0606.000608 pmid: 11076718

[68]	Cheng V C C, Hung I F N, Tang B S F, et al. Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome. Clinical Infectious Diseases, 2004,38(4):467-475.

[69]	Puthucheary J, Lim D, Chan I, et al. Severe acute respiratory syndrome in Singapore. Archives of Disease in Childhood, 2004,89(6):551-556. pmid: 15155402

[70]	Ding Y Q, He L, Zhang Q L, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. The Journal of Pathology, 2004,203(2):622-630. doi: 10.1002/path.1560 pmid: 15141376

[71]	Peiris J S M, Lai S T, Poon L L M, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. The Lancet, 2003,361(9366):1319-1325.

[72]	Leung C H, Gomersall C D. Middle east respiratory syndrome. Intensive Care Med, 2014,40(7):1015-1017.

[73]	Assiri A, Al-Tawfiq J A, Al-Rabeeah A A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet Infectious Diseases, 2013,13(9):752-761. pmid: 23891402

[74]	Chen N S, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020,395(10223):507-513.

[75]	房晓伟, 梅青, 杨田军, 等. 2019新型冠状病毒感染的肺炎79例临床特征及治疗分析. 中国药理学通报, 2020,36(4):1-7.

[75]	Fang X W, Mei Q, Yang T J, et al. 2019 novel coronavirus pneumonia: clinical characteristics and treatment analysis of 79 cases. Chinese Pharmacological Bulletin, 2020,36(4):1-7.

[76]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020,395(10223):497-506.

[77]	Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr, 2020,87(4):281-286. doi: 10.1007/s12098-020-03263-6 pmid: 32166607

[78]	中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎防控方案(第六版).[2020-08-18]. http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtml.

[78]	National Health Commission of the People’s Republic of China. Novel coronavirus pneumonia prevention and control program (Sixth Edition). [2020-08-18]. http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtml.

[79]	Gao Z, Xu Y, Sun C, et al. 新型冠状病毒肺炎防控方案(第六版).[2020-08-18]. https://www.sciencedirect.com/science/article/pii/S1684118220301134.

[80]	中华人民共和国国家卫生健康委员会. 关于新型冠状病毒无症状感染者的防控工作答问.[2020-08-18]. http://www.nhc.gov.cn/jkj/s3578/202003/718c79c96f3e46409dd49303d41a00ef.shtml.

[80]	National Health Commission of the People’s Republic of China. Questions about novel coronavirus asymptomatic infection prevention and control.[2020-08-18]. http://www.nhc.gov.cn/jkj/s3578/202003/718c79c96f3e46409dd49303d41a00ef.shtml.

[81]	Li Q, Ding X, Xia G, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study. E Clinical Medicine. 2020,23:100375.

[82]	Pene F, Merlat A, Vabret A, et al. Coronavirus 229E-related pneumonia in immunocompromised patients. Clinical Infectious Diseases, 2003,37(7):929-932. doi: 10.1086/377612 pmid: 13130404

[83]	Monto A S. Coronaviruses. The Yale Journal of Biology and Medicine, 1974,47(4):234-251.

[84]	Tyrrell D A J, Cohen S, Schilarb J E. Signs and symptoms in common colds. Epidemiol Infect, 1993,111(1):143-156. doi: 10.1017/s0950268800056764 pmid: 8394240

[85]	Abdul-Rasool S, Fielding B C. Understanding human coronavirus HCoV-NL63. The Open Virology Journal, 2010,4(1):76-84.

[86]	Woo P C Y, Lau S K P, Chu C M, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. Journal of Virology, 2004,79(2):884-895. pmid: 15613317

[87]	Gaunt E R, Hardie A, Claas E C J, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. Journal of Clinical Microbiology, 2010,48(8):2940-2947. doi: 10.1128/JCM.00636-10 pmid: 20554810

[88]	Fang F, Luo X P. Facing the pandemic of 2019 novel coronavirus infections the pediatric perspectives. Chin J Pediatr, 2020,58(2):81-85.

[89]	Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 Coronavirus disease in China. Pediatrics, 2020,58(4):712-713.

[90]	Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020,383(18):1708-1720. doi: 10.1056/NEJMp2016293 pmid: 32678529

[91]	Song W L, Li J H, Zou N, et al. Clinical features of pediatric patients with coronavirus disease (COVID-19). Journal of Clinical Virology, 2020,127:104377. doi: 10.1016/j.jcv.2020.104377 pmid: 32361323

[92]	Wu Z, McGoogan J M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020,323(13):1239-1242. doi: 10.1001/jama.2020.2648 pmid: 32091533

[93]	Zainab S, Ricci K, Brendan M, et al. COVID-19 and older adults: what we know. JAGS, 2020,68(5):926-929.

[94]	Wan Y, Shang J, Graham R, et al. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decadelong structural studies of SARS. J Virology, 2020, DOI: 10.1128/JVI.00127-20. doi: 10.1128/JVI.00127-20 pmid: 33239453

[95]	Li X C, Zhang J, Zhuo J L. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res, 2017,125(PtA):21-38.

[96]	Lei F, George K, Michael R. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection. The Lancet, 2020,8(4):e21. doi: 10.1016/S2213-2600(20)30116-8 pmid: 32171062

[97]	Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 criticallyill patients with COVID-19 in Washington State. JAMA, 2020,323(16):1612-1614. doi: 10.1001/jama.2020.4326 pmid: 32191259

[98]	Li B, Yang J, Zhao F M, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology, 2020,109(5):531-538. pmid: 32161990

[99]	Zhang L, Jiang Y, Wei M, et al. Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province. Chin J Obstet Gynecol, 2020, DOI: 10.3760/cma.j.cn112141-20200218-00111/. doi: 10.3760/cma.j.cn112141-20200218-00111

[100]	Wendy N P, Olive P K. Is pregnancy a risk factor of COVID-19. EUR J OBSTET GYN R B, 2020,252:605-609.

[101]	Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 2005,11(8):875-879. doi: 10.1038/nm1267 pmid: 16007097

[102]	中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第七版).[2020-08-18]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.

[102]	National Health Commission of the People’s Republic of China. Diagnosis and treatment of novel coronavirus pneu- monia (trial version seventh).[2020-08-18]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.

[1]	ZHANG Sai,XIANG Le,LI Lin-hai,LI Hui-jun,WANG Gang,QIAN Chun-gen. Development and Performance Evaluation of A Rapid IgM-IgG Combined Antibody Test for 2019 Novel Coronavirus Infection[J]. China Biotechnology, 2020, 40(8): 1-9.

[2]	WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.

[3]	XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.

[4]	GONG Yue,LIAO Qing-yun,YU Qian-qian,SHI Zhi-xiang,CHEN Jing,ZHANG Yu-hui,ZHAO Guang-hui. A Bibliometric Analysis on Coronaviruses[J]. China Biotechnology, 2020, 40(1-2): 21-37.

[5]	ZHAO Ping,YANG Yan-ping. Patent Situation Analysis of Diagnosis Technology for Coronavirus Infection in Human[J]. China Biotechnology, 2020, 40(1-2): 51-56.

[6]	LI Dong-qiao,LV Lu-cheng,YANG Yan-ping. The Research Status and Development Trend of Global Human Coronavirus Antibody Field[J]. China Biotechnology, 2020, 40(1-2): 65-70.

[7]	CHENG Yong-qing,LIU Jin-yi,LIN Fu-Yu,TONG Mei. Novel Coronavirus Control and the Important Contribution of Interferon α1b[J]. China Biotechnology, 2020, 40(1-2): 71-77.

[8]	WANG Guo-qiang,YU Yin-yin,ZENG Hua-hui,WANG Xu-dong,WU Yu-bin,SHANG Li-zhi,LI Yu-lin,ZHANG Yi-qing,ZHANG Xi-xi,ZHANG Zhen-qiang,WANG Yun-long. Preparation of Quality Control Materials for RT-PCR Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Based on MS2 Phage Virus-like Particles[J]. China Biotechnology, 2020, 40(12): 31-40.

[9]	CHEN Li-jun,QU Jing-jing,XIANG Charlie. Therapeutic Potentials, Clinical Studies, and Application Prospects of Mesenchymal Stem Cells in 2019 Novel Coronavirus (COVID-19)[J]. China Biotechnology, 2020, 40(11): 43-55.

[10]	SHEN Liang, TAN Wen-jie. Progress on the Technique and its Application of Reverse Genetics for Coronaviruses[J]. China Biotechnology, 2015, 35(2): 84-91.

[11]	GU Yuan-xing, WANG Meng, LIU Wen-qian, ZHANG Jie, LIU Yong-sheng. The Application Prospects of Ovine Adenovirus287 Vector[J]. China Biotechnology, 2011, 31(03): 101-106.

Viewed

Full text

Abstract

Cited

Shared

Discussed